• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硫嘌呤类药物的添加可以使对肿瘤坏死因子单药治疗应答丧失的克罗恩病患者重新获得应答。

Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.

机构信息

Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia; Department of Gastroenterology, National University Hospital, Singapore.

出版信息

J Gastroenterol Hepatol. 2013 Oct;28(10):1595-9. doi: 10.1111/jgh.12263.

DOI:10.1111/jgh.12263
PMID:23662928
Abstract

BACKGROUND AND AIM

Anti-tumor necrosis factor (TNF) antibodies are effective in maintaining remission in Crohn's disease. However, a significant proportion of patients lose response to these agents with time. This study aimed to determine whether the introduction of a thiopurine in patients who have lost response to anti-TNF monotherapy results in regained response.

METHODS

Five patients (four males; aged 22-38 years) with active Crohn's disease, who had an initial response to anti-TNF therapy but had lost response, were commenced on azathioprine or mercaptopurine at standard doses while continuing anti-TNF therapy. All had previously failed thiopurine therapy prior to starting anti-TNF treatment.

RESULTS

All patients experienced improved clinical symptoms within 2-6 months, with benefit sustained over a mean follow-up of 19 months. Two patients with an elevated C-reactive protein at the time of thiopurine addition demonstrated a fall in C-reactive protein. Colonoscopy before and after thiopurine addition in four patients showed improvement in all, with mucosal healing achieved in two. No adverse effects of treatment were noted.

CONCLUSIONS

Addition of a thiopurine in patients who have lost response to anti-TNF monotherapy is an effective strategy to recapture response even if the patient has previously failed thiopurine therapy. Thiopurines may reduce immunogenicity or act synergistically with anti-TNF therapy.

摘要

背景与目的

抗肿瘤坏死因子(TNF)抗体在维持克罗恩病缓解方面非常有效。然而,随着时间的推移,相当一部分患者对这些药物失去了反应。本研究旨在确定在对 TNF 单药治疗失去反应的患者中引入硫嘌呤是否会导致再次应答。

方法

5 名(男 4 例;年龄 22-38 岁)患有活动期克罗恩病的患者,他们对 TNF 治疗有初始反应,但已失去反应,开始给予标准剂量的硫唑嘌呤或巯基嘌呤,同时继续 TNF 治疗。所有患者在开始 TNF 治疗前均已对硫嘌呤治疗失败。

结果

所有患者在 2-6 个月内临床症状均得到改善,平均随访 19 个月时仍持续获益。2 名在添加硫嘌呤时 C 反应蛋白升高的患者,C 反应蛋白下降。4 例患者在添加硫嘌呤前后行结肠镜检查,均显示所有患者均有改善,其中 2 例达到黏膜愈合。未观察到治疗的不良反应。

结论

在对 TNF 单药治疗失去反应的患者中添加硫嘌呤是一种有效的策略,可以重新获得应答,即使患者之前对硫嘌呤治疗失败。硫嘌呤可能会降低免疫原性或与 TNF 治疗协同作用。

相似文献

1
Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.硫嘌呤类药物的添加可以使对肿瘤坏死因子单药治疗应答丧失的克罗恩病患者重新获得应答。
J Gastroenterol Hepatol. 2013 Oct;28(10):1595-9. doi: 10.1111/jgh.12263.
2
Phenotypic features of Crohn's disease associated with failure of medical treatment.与药物治疗失败相关的克罗恩病的表型特征。
Clin Gastroenterol Hepatol. 2014 Mar;12(3):434-42.e1. doi: 10.1016/j.cgh.2013.08.026. Epub 2013 Aug 24.
3
[Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].[抗TNFα抗体治疗瘘管性克罗恩病的疗效]
Przegl Lek. 2011;68(9):602-5.
4
Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.阿达木单抗治疗既往未接受其他抗 TNF 治疗的儿童克罗恩病患者的长期疗效。
J Crohns Colitis. 2010 Nov;4(5):594-8. doi: 10.1016/j.crohns.2010.04.002. Epub 2010 May 1.
5
Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.3个月时的黏膜愈合可预测抗TNF治疗的腔内克罗恩病的长期内镜缓解。
Scand J Gastroenterol. 2013 May;48(5):543-51. doi: 10.3109/00365521.2013.772230. Epub 2013 Mar 12.
6
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.英夫利昔单抗诱导治疗对肿瘤坏死因子拮抗剂治疗失败的克罗恩病患者的影响。
Gastroenterology. 2014 Sep;147(3):618-627.e3. doi: 10.1053/j.gastro.2014.05.008. Epub 2014 May 21.
7
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.向 FDA AERS 报告的使用肿瘤坏死因子-α(TNF-α)抑制剂的 T 细胞非霍奇金淋巴瘤:REFURBISH 研究结果。
Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.
8
Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.MRI 引导下长期联合使用抗 TNF-α 药物和巯嘌呤治疗克罗恩病肛周瘘管。
Inflamm Bowel Dis. 2012 Oct;18(10):1825-34. doi: 10.1002/ibd.21940. Epub 2012 Jan 4.
9
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?世界胃肠病学大会与欧洲克罗恩病和结肠炎组织关于 IBD 的生物治疗的伦敦立场声明:何时开始,何时停止,选择哪种药物,以及如何预测应答?
Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213. doi: 10.1038/ajg.2010.392. Epub 2010 Nov 2.
10
Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.在难治性克罗恩病患儿中联合使用甲氨蝶呤和抗 TNF-α 治疗:病例系列研究。
Inflamm Bowel Dis. 2012 Aug;18(8):1488-92. doi: 10.1002/ibd.21885. Epub 2011 Aug 31.

引用本文的文献

1
Controversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus.抗 TNF 治疗克罗恩病患者管理中的争议:德尔菲共识。
BMJ Open Gastroenterol. 2024 Jan 23;11(1):e001246. doi: 10.1136/bmjgast-2023-001246.
2
Therapeutic Antibodies in Medicine.医学中的治疗性抗体。
Molecules. 2023 Sep 5;28(18):6438. doi: 10.3390/molecules28186438.
3
Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
免疫调节剂联用可促进炎症性肠病患者对抗 TNF 治疗的药物抗体介导应答丧失的逆转。
Int J Colorectal Dis. 2023 Feb 25;38(1):54. doi: 10.1007/s00384-023-04349-1.
4
Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.培戈洛酶联合免疫调节治疗在改善难治性痛风疗效、安全性和反应持久性中的专家意见。
Curr Rheumatol Rep. 2022 Jan;24(1):12-19. doi: 10.1007/s11926-022-01055-9. Epub 2022 Feb 15.
5
The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease.免疫调节剂在预防和抑制炎症性肠病中抗肿瘤坏死因子治疗的抗药抗体方面的疗效。
Ann Gastroenterol. 2022 Jan-Feb;35(1):1-7. doi: 10.20524/aog.2021.0682. Epub 2021 Dec 6.
6
Current review of the management of fistulising perianal Crohn's disease.肛周克罗恩病肛瘘管理的当前综述
Frontline Gastroenterol. 2020 Aug 13;12(6):515-523. doi: 10.1136/flgastro-2020-101489. eCollection 2021.
7
Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study.在治疗克罗恩病时,英夫利昔单抗治疗应答丢失后加用硫唑嘌呤与早期联合治疗的疗效比较:一项回顾性研究。
Dig Dis Sci. 2021 Sep;66(9):3124-3131. doi: 10.1007/s10620-020-06600-z. Epub 2020 Sep 13.
8
Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?优化炎症性肠病的生物治疗:治疗药物监测有多重要?
Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):702-710. doi: 10.1038/s41575-020-0352-2. Epub 2020 Sep 2.
9
Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?治疗性单克隆抗体的个体化剂量——治疗范式的改变?
AAPS J. 2018 Sep 5;20(6):99. doi: 10.1208/s12248-018-0257-y.
10
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.炎症性肠病中治疗性抗体的药物抗体产生、预防和管理:实用概述。
Drugs. 2017 Mar;77(4):363-377. doi: 10.1007/s40265-017-0693-5.